Industry & Policy News

[SCG Cell Therapy] SCG Cell Therapy and the Agency for Science, Technology and Research (A*STAR) announced the launch of joint laboratories for cellular immunotherapies. This collaboration,aims to advance the development of iPSC technology to produce novel cell therapies that meet GMP standards.

[University of Waterloo] Canada will not reach the original World Health Organization's (WHO) target of eliminating the Hepatitis C virus by 2030 and lags in comparison to other developed countries, a new study led by researchers at the University of Waterloo has found.

[Evaxion Biotech A/S] Evaxion Biotech A/S announced that the first patient in its EVX-01 Phase II trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA®. The company initiated its Phase II clinical study to assess the efficacy, safety, and ability to induce a tumor-specific immune response of the EVX-01 cancer vaccine in metastatic melanoma patients.

[Innate Pharma] Innate Pharma SA announced that the first patient was dosed in the Phase II dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101, evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs.

[BBC] The University of Sheffield was given more than £2.5m funding to look into dormant cancer cells and develop new treatments for myeloma, a type of blood cancer.

[University of Arkansas for Medical Sciences] Researchers at the University of Arkansas for Medical Sciences (UAMS) will use a $2.27 million grant from the NIH to answer key questions about the cellular mechanisms used by estrogen to prevent bone loss and osteoporosis.